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Background. To explore the relationship between Toll-like rpheral blood mononuclear cells (PBMC) and systemic inﬂammatory
response syndrome (SIRS) in postoperative patients of liver transplantation (LT). Methods. Blood samples of 27 patients receiving
LT were collected at T1 (after induction of anaesthesia), T2 (25 minutes after the beginning of anhepatic phase), T3 (3 hours after
graft reperfusion), and T4 (24 hours after graft reperfusion). The expression of TLR2/4 on PBMC and serum concentration of
tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-8 were measured. The patients were divided into SIRS group (n = 12)
a n dn o n - S I R Sg r o u p( n = 15) for analysis. Results. Blood loss and transfusion were higher in the SIRS group than in the non-
SIRS group. Both the preanhepatic and anhepatic phase were signiﬁcantly longer in the SIRS group. The TLR2/4 expression on
PBMC as well as serum TNF-α,I L - 1 β, and IL-8 were signiﬁcantly higher at T3 and T4 than that at T1 and T2 in the SIRS patients.
The expression of TLR4 on PBMC is positively correlated to serum TNF-α, IL-8. Expression of TLR2/4 on PBMC and serum
concentrationsofTNF-α,IL-1β,didnotdiﬀeramongthe4-timepointsinnon-SIRSpatients.Conclusions.UpregulationofTLR2/4
expression on PBMC may contribute to the development of postoperative SIRS during perioperative period of LT.
1.Introduction
Orthotopic liver transplantation (OLT) is the most eﬀective
and the best therapeutic solution for ﬁnal stage liver
diseases. More than 60,000 patients receive OLT every
year worldwide [1]. Systemic inﬂammatory response syn-
drome(SIRS) often accompanies sepsis, trauma, hypoxia,
and ischemia-reperfusion injury (IRI) [2–4]. The activation
of mononuclear phagocytes, and consequently release of
massive amount of proinﬂammatory cytokines may lead to
multiorgan dysfunction syndrome (MODS) [3, 4]. SIRS is
a common feature after major surgery [5, 6]. In recent years,
SIRShasbeeninterpretedasawarningsignforpostoperative
complications and organ failure [7–9]. Speciﬁcally, longer
SIRS duration has been associated with poor outcomes after
surgery [5, 6, 8, 9].
Toll-like receptors (TLRs) play an important role in
many pathophysiological processes such as inﬂammation
and IRI [10–14]. TLR2 and TLR4 are members of the TLRs
family [13, 14], and could initiate inﬂammatory responses to
various stimuli [2, 15].
A previous study in this laboratory revealed increased
expression of TLR2/4 in mononuclear and proinﬂammatory
cytokines in liver transplantation [16]. Based on this ﬁnding,
we speculate that TLR2/4 may also contribute to the
development of SIRS during OLT. In the current study, we
examined the expression of TLR2/4 on PBMC in a group of
OLT patients with SIRS, and compared the results to that in
a group of patients without SIRS.
2. Patients andMethods
This study wasapproved by the ResearchEthics Board of The
Third Aﬃliated Hospital, Sun Yat-sen University. Written
informed consent was obtained from all patients prior to the
enrollment.2 Mediators of Inﬂammation
Table 1: Basic characteristics of the study population.
Total patient (n) 27
Gender (M : F) 24 : 3
Age (years) 47 ±11
Weight (kilogram) 64 ±10
C T Ps c o r e( A:B:C ) 1 0:5:1 2
Diagnosis
hepatitis B virus cirrhosis (n) 12
hepatitis B virus cirrhosis accompanied
with small liver cancer (n)
8
chronic severe hepatitis B (n) 4
acute liver failure induced by drug (n) 3
Physical Status (III : IV) 10 : 17
Mean ±SD or median (Q).
2.1. Study Population. Twenty-seven patients (24 males and
3 females) with end-stage liver diseases undergoing modiﬁed
piggyback liver transplantation were enrolled. Among these
patients, 12 had hepatitis B cirrhosis, 8 had small liver cancer
(tumor diameter < 3 centimeter) on a hepatitis B back-
ground, 4 had chronic severe hepatitis B and the remaining 3
had drug-related acute liver failure. Liver function based on
modiﬁed Child-Pugh classiﬁcation [17] was A in 10 patients,
B in 5 patients, and C in the remaining 12 patients. Physical
status of the patients was III or IV according to the American
Society of Anesthesiologists (ASA) classiﬁcation (Table 1).
The status of organ donors was cardiac death in 8 cases,
brain death in 10 cases, and living relatives in 9 cases.
Warm ischemia for donation after cardiac death was 3 to
4.5 minutes (Table 2). There was no warm ischemia in other
cases.
2.2. Anesthesia. Anesthesia was induced with intravenous
(i.v.) fentanyl and propofol. Tracheal intubation was facili-
tated with rocuronium. The lungs were mechanically venti-
lated with oxygen (50%). Partial pressure of carbon dioxide
(PETCO2) was maintained at 30–35mmHg. Anesthesia was
maintained with isoﬂurane and intermittent i.v. of fentanyl.
Blood pressure was maintained with dopamine infusion if
necessary. Body temperature was keep at 36∼37◦Cb ya
convective air warming system and ﬂuid warming system. To
avoid interference of measurements of TLR2/4 expression on
mononuclear cells, no whole blood was transfused during
operation. Only concentrated red blood cells, fresh frozen
plasmaandcryoprecipitateweretransfusedduringoperation
according to monitoring.
2.3. Surgical Procedure. All patients received modiﬁed piggy-
back liver transplantation with venous reformation and no
veno-venous bypass (VVBP). Surgical management of ﬁrst
and second hepatic hilums is similar to classic orthotopic
liver transplantation but without short hepatic vein disposal.
After disconnection of the ﬁrst hepatic hilum, vena cava
was interrupted by a satinskys clamp from the back of the
liver. Vena cava of second hepatic hilum was blocked by a
Klintmalm liver clamp. The liver was then removed. The
openings of hepatic veins on the anterior wall of the vena
cava were connected to form an open inverted triangular
cuﬀ. The posterior wall of the donor inferior vena cave (IVC)
was incised to fashion a wide-open inverted triangular cuﬀ
that matched the IVC opening in the recipient. The openings
were closed with 4–0 Prolene suture. The graft was ﬂushed
with 400 to 800ml cold FFP. Donor infrahepatic vena cava
was ligated, and the portal vein was anastomosized. The
clamps were then removed to allow reperfusion. Hepatic
artery and bile duct anastomoses were completed [18–20].
The entire procedure consisted of an anhepatic phase
(from vascular clamping to reperfusion of portal vein and
inferiorvenacava)andaneohepaticphase(fromreperfusion
of donor liver to the end of operation).
2.4. Collection of General Data. The demographic data
as well as the Child-Turcotte-Pugh (CTP) scores, ASA
classiﬁcation, duration of the operation, volume of blood
loss and input were collected. Duration of postoperative
mechanical ventilation, alanine aminotransferase (ALT),
aspartate aminotransferase (AST), prothrombin time (PT),
bloodureanitrogen(BUN),andserumcreatinine(SCr)were
also recorded.
2.5. Collection of Blood Samples. Whole blood (4mL) was
collected at T1 (after induction of anaesthesia), T2 (25
minutes after the beginning of anhepatic phase), T3 (3
hours after graft reperfusion), and T4 (24 hours after graft
reperfusion). Two mL of blood sample was collected in
EDTA tubes for analysis of TLR2/4 immediately with ﬂow
cytometry. The remaining two mL of blood sample was
collected in dry tubes for TNF-α,I L - 1 β, and IL-8 assay.
2.6. Analysis of TLR2/4 Expression. Twenty μLa l l o p h y c o -
cyanin (APC) antihuman CD14 (eBioscience) plus 20μLﬂ u -
oresceinisothiocyanate (FITC) antihuman Toll-like receptor
2(eBioscience,SanDiego,California,USA)orphycoerythrin
(PE) antihuman Toll-like receptor 4 (eBioscience) were
added to 100μL of EDTA treated blood. The mixture was
incubatedfor20minutesinthedarkatambienttemperature.
After which, they were mixed with 2mL of RBC Lysis Buﬀer
(eBioscience)inthedarkfor15minutesandthencentrifuged
for 5 minutes at 300g. After rinsing twice, the supernatant
was discarded and sample was preserved at 4◦C in the dark.
Samples were quantiﬁed with FACs Calibur ﬂow cytometry
(Becton Disckinson, Franklin Lakes, New Jersey, USA). The
isotype controls were FITC mouse IgG2α and PE mouse
IgG2α (eBioscience).
2.7. Cytokine Assay. TNF-α,I L - 1 β,a n dI L - 8w e r em e a s u r e d
with ELISA (Rapidbio, West Hills, California, USA).
2.8. Perioperative SIRS Monitoring. Patients’ temperature,
heart rate, respiratory rate, and white blood cell count were
assessed every 6 hours for 7 days after the operation. The
diagnosis of SIRS was based on the presence of two or more
of the following criteria [21], veriﬁed by an ICU physician as
well as an anesthesiologist: (1) temperature >38◦Co r<36◦C,Mediators of Inﬂammation 3
Table 2: Postoperative SIRS in patients receiving diﬀerent categories of transplant.
SIRS non-SIRS
n Warm ischemia
times (min)
∗
Cold ischemia
times
# (h)
n Warm ischemia
times (min)
Cold ischemia
times (h)
No heart beat donors 3 4.3 ±0.65 .0 ±2.6 5 4.4 ±0.46 .4 ±0.5
Living-related donors 5 01 .0 ±0.3 4 01 .3 ±0.5
Brain dead donors 4 02 .0 ±0.8 6 01 .3 ±0.5
Total 12 0 (3) 1.8 (2) 15 0 (4) 1.5 (5)
Mean±SD or median (Q).
∗Warm ischemia time was deﬁned as the time between discontinuation of blood perfusion and initiation of aortic or hepatic arterial perfusion with the cold
preservation solution.
#Cold ischemia time was deﬁned as the time from aortic or hepatic arterial perfusion with cold preservation solution until reperfusion.
Table 3: Clinical characteristics in SIRS versus non-SIRS during OLT.
Features Total SIRS non-SIRS
n 27 12 15
G e n d e r( M:F ) 2 4:3 1 1:1 1 3:2
Age (years) 47 ±11 48 ±11 47 ±12
Weight (kilogram) 64 ±10 61 ±86 6 ±11
C T Ps c o r e( A:B:C ) 1 0:5:1 2 4:2:6 6:3:6
Ascites (mL) 622 ±1305 775 ±983 500 ±1538
Urine (mL) 1541 ±699 1455 ±567 1609 ±801
Volumes of blood loss (mL) 3011 ±1286 3617 ±1380
∗ 2527 ±1004
Concentrated red blood cell (mL) 989 ±536 1225 ± 554
∗ 800 ±453
Pre-anhepatic phase (min) 105 ±44 125 ± 55
∗ 89 ±24
Anhepatic phase (min) 46 ±22 55 ±30
∗ 38 ±8
Neohepatic phase (min) 252 ±46 242 ±26 259 ±57
Total operation time (min) 402 ±65 422 ±65 386 ±63
Mean ±SD or median (Q), ∗P<. 05, compared with non-SIRS.
(2) heart rate >90 per minute, (3) respiratory rate >20 per
minute or PaCO2 < 32mmHg, and (4) white blood cell
count >12,000/mL, <4,000/mL, or >10% immature (band)
forms.
2.9. Data Analysis. The data are expressed as mean ±
standard deviation. One-Way ANOVA was used to analyze
the diﬀerence between the diﬀerent phases in the same
group. Independent-samples t-test was used to analyze
the diﬀerence between the SIRS and non-SIRS groups.
Data of nonnormal distribution are expressed as median
(interquartile range) [Median (Q)], and were analyzed by
Wilcoxon signed ranks test. Spearman correlation analysis
was used to determine the relationship between diﬀerent
measures. P<. 05 is considered statistically signiﬁcant. All
data were processed by SPSS12.0 for windows (SPSS Inc.,
Chicago, Ill, USA).
3. Results
3.1. General Data. Twelve out of 27 patients developed
SIRS after OLT (at 6 to 78 hours), and two died of lung
infection. There were no signiﬁcant diﬀerences between
two groups on graft origination, duration of cold or warm
ischemia (Table 2). Blood loss and concentrated red blood
cell (RBC) transfusion during the operation were larger
in the SIRS group than in the non-SIRS group. The pre-
anhepatic phase and anhepatic phase lasted longer in SIRS
patients (Table 3) .C T Ps c o r e ,a g e ,g e n d e r ,b o d yw e i g h t ,
ascites, urinary production, the length of neohepatic phase
or the entire operation did not diﬀer between the SIRS and
non-SIRS groups (Table 3).
Duration of postoperative mechanical ventilation in the
SIRS group was signiﬁcantly longer than non-SIRS group.
Hepatic function, renal function, and infection (respiratory
tract) after the surgery also did not diﬀer between the 2
groups (Table 4).
3.2. Diﬀerence of TLR2/4 Expression on PBMC between SIRS
and Non-SIRS Groups. The baseline TLR2 on PBMC was
74% (interquartile range: 25%) and 80% (interquartile
range: 28%) in SIRS and non-SIRS groups (P>. 05,
Figure 1). Baseline TLR4 was 12% (interquartile range: 8%)
and 18% (interquartile range: 21%) in SIRS and non-
SIRS groups (P>. 05, Figure 2). TLR 2 expression was
signiﬁcantly higher at T3 and T4 in comparison to T1 and
T2 in the SIRS patients but not in the non-SIRS group4 Mediators of Inﬂammation
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Figure 1: Representative FACS plots of TLR2 staining on PBMC. (a) SIRS; (b) non-SIRS. The non-speciﬁc binding is relatively small relative
to speciﬁc binding as deﬁned by the isotype controls. Dotted line represents the isotype control.
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Figure 2: Representative FACS plots of TLR4 staining on PBMC. (a) SIRS; (b) non-SIRS. The non-speciﬁc binding is relatively small relative
to speciﬁc binding as deﬁned by the isotype controls. Dotted line represents the isotype control.
(Figure 3). Similar changes were found for TLR4 expression
(Figure 4).
The expression of TLR2/4, and particularly relative
increase at T3/4 over T1, in two died patients were higher
than the average.
3.3. Diﬀerence of the Serum Levels of TNF-α,I L - 1 β and IL-8
between SIRS and Non-SIRS Groups. Baseline TNF-α,I L - 1 β,
and IL-8 was 90 (interquartile range: 118), 34(interquartile
range: 239), and 163(interquartile range: 181) pg/mL in SIRS
group, and 96(interquartile range: 488), 38(interquartile
range: 161), and 64(interquartile range: 173) pg/mL in the
non-SIRS group, respectively. Serum TNF-α,I L - 1 β,a n dI L - 8
was signiﬁcantly higher at T3 and T4 in comparison to T1
and T2 in the SIRS group, but not in the non-SIRS group
(Figures 5, 6,a n d7).
3.4. Correlation Analysis. There was no relationship between
TLR2/4 and CTP score. The expression of TLR4, but
not TLR2, was positively correlated to serum TNF-αMediators of Inﬂammation 5
Table 4: Postoperative clinical characteristics in SIRS versus non-
SIRS.
SIRS non-SIRS
(n = 12) (n = 15)
Duration of mechanical
ventilation (h) 19 (44)
∗ 11 (9)
ALT (U/L) 530 ±268 655 ±410
AST (U/L) 136 (153) 60 (112)
PT (s) 17 ±41 6 ±2
BUN (mmol/L) 19 ±11 13 ±6
Cr (μmol/L) 102 ±56 92 ±40
Pulmonary infecttion 9/12 6/15
Mean ±SD or median (Q), ∗P<. 05, compared with the non-SIRS group.
ALT = alanine aminotransferase; AST = aspartate aminotransferase; PT =
prothrombin time; BUN = blood urea nitrogen; SCr = serum creatinine.
Duration of postoperative mechanical ventilation in the SIRS group was
signiﬁcantly longer than non-SIRS group. Hepatic function, renal function
and pulmonary infecttion after the surgery also did not diﬀer between the
2g r o u p s .
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Figure 3: Upregulation of TLR2 expression on PBMC. Mean ± SD
(n = 12 for SIRS; n = 15 for non-SIRS); ∗P<. 01, #P<. 05,
compared with T1/T1.
(r = 0.310, P = .029), and IL-8 (r = 0.304, P = .025) in
the SIRS group but not in the non-SIRS group. In the SIRS
patients, the increase of TLR4 at T4 was positively correlated
with the length of anhepatic phase (r = 0.688, P = .013).
4. Discussion
The current study demonstrated that expression of TLR2/4
on PBMC and concentration of inﬂammatory cytokines
after liver transplant reperfusion were signiﬁcantly higher in
patients with SIRS than those without.
SIRS is an inﬂammatory state caused by serious trauma,
and infection [2–4, 21]. A cardinal feature of SIRS is
the activation of inﬂammatory cells such as monocyte-
macrophages, neutrophils, and massive release of proin-
ﬂammatory cytokines [2, 4]. SIRS is common in OLT due
to surgical trauma, hemorrhage, and ischemia-reperfusion
injury. Incidence of postoperative SIRS in our study is 44%.
TLR2/4 on immune cells can activate nuclear factor
k a p p aB( N F - κB) and activator protein-1 (AP-1) in response
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Figure 4: Upregulation of TLR4 expression on PBMC. Mean ± SD
(n = 12 for SIRS; n = 15 for non-SIRS); ∗P<. 01, #P<. 05,
compared with T1/T1.
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Figure 5: Increase of serum TNF-α. Median (Q) n = 12 for SIRS;
(n = 15 for non-SIRS); ∗P<. 05, compared with T1/T1.
to a variety of pathological conditions, which in turn
initiate or amplify inﬂammation, and ultimately, organ
injury [11–14]. Lipopolysaccharide (LPS) can induce TLR4
gene expression in granulocyte and endothelial cells, and
activate NF-κB and the production of TNF-α,I L - 6 ,a n d
IL-8 [22]. TLR4 antibody can inhibit activation of NF-κB
and production of inﬂammatory cytokines [23]. Previous
studies also demonstrated that high expression of TLR4 is
positively correlated with ischemia-reperfusion injury [24].
Importantly, the transcriptional and translational signal of
TLR2/4 in mononuclear cell was upregulated signiﬁcantly in
SIRS patients [25].
Although there was no signiﬁcant diﬀerence in CTP
scores between the SIRS and non-SIRS groups, the expres-
sion of TLR2/4 on PBMC and serum proinﬂammatory
cytokines at T3 and T4 were signiﬁcantly higher in the SIRS
group. The increase of TNF-α,I L - 1 β or IL-8 was also posi-
tively correlated with the expression of TLR4 in monocytes
in the SIRS group, suggesting that high expression of TLR2/4
in OLT patients is associated with SIRS.
Previous studies indicated that cytokine, endotoxin are
involved in the regulation of TLR2/4 expression [26–30].
Within the contextoflivertransplantation, factorsthatcould6 Mediators of Inﬂammation
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Figure 6: Increase of serum IL-1β. Median (Q) (n = 12 for SIRS;
n = 15 for non-SIRS); ∗P<. 05, compared with T1/T1.
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Figure 7: Increase of serum IL-8. Median (Q) (in SIRS group, n =
12; in non-SIRS group, n = 15); ∗P<. 05, compared with T1/T1.
upregulate TLR2/4 may include prolonged surgery, mas-
sive blood loss and transfusion, liver ischemia/reperfusion,
translocation of enteric microbes during portal vein occlu-
sion and reopening, and ischemia-reperfusion injury of graft
[31–33]. Speciﬁcally, blood loss, the length of preanhepatic
phase and anhepatic phase may be the most important
factors for upregulation of TLR2/4 expression in PBMC after
OLT.
In conclusion, our ﬁndings suggest that upregulation of
TLR2/4 on PBMC could initiate SIRS after major surgery
such as OLT.
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